Evidence Based Hair

Season 4, Episode7 (Tinea with baricitinib, ADHD and AA, Upadacitinib for AA, Baricitinib 52 week data, micro needling for MPHL)

Season 4, Episode 7 Data

Season 4, Episode 6 (Scalp Neuropathy in DMS, Scurvy, Cutaneous Pili Migrans, Quiz Case, Beethoven’s Hair)

Season4, Episode 6

Season 4, Episode 5 (Hair Loss after COIVD Vaccines, FD in DEB, New DSC ”CVG” Variants, DSC After HT, DLE to SLE Progression)

Season 4, Episode 5

Season 4, Episode 4 (COVID hair loss, TE from anti-CGRP migraine meds, tinea capitis, oral minoxidil for traction alopecia

Season 4 Episode 4
 
COVID RELATED TE
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol.  2023 Mar 8.
M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060.
Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666.
Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9
Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16. 
Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002
 
HAIR LOSS FROM ANTI-CGRP THERAPIES
Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.
 
Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227
 
Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.
 
ORAL MINOXIDIL FOR TRACTION ALOPECIA
Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5.
Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.
Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.
 
TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

Season 4 Episode 3 (Spironolactone for FPHL, Oral Minoxidil for Nails, Histology of AA vs AGA, AAI, Work Productivity in AA)

Season 4, Episode 3

Season 4, Episode 2 (Scalp Bx for Black Women, Oral Minoxidil for Chemotherapy Hair Loss, Folliculotropic MF, Atrichia with Papular Lesions, MTX and Liver Fibrosis)

STUDIES REFERENCED
 
ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS
 
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3. 
 
ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS
 
Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.
 
 
FOLLICULOTROPIC MYCOSIS FUNGOIDES
 
Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26. 
Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180
Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports.  2021 May 18;11(1):10555.
 
 
ATRICHIA WITH PAPULES LESIONS
 
Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562.
Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890
Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349.
Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.
 
 
METHOTREXATE AND LIVER FIBROSIS
Atallah  E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.
 
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162
 
Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.

Season 4, Episode 1 (HCQ and Retinopathy Risk, FD Microbiome, LDN for LPP, TNF Inhibitors for DSC)

STUDIES REFERENCED
 
PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA
 
Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25.
 
 
HYDROXYCHLOROQUINE AND RETINOPATHY RISK
 
Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17.
 
LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS
 
Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020
 
Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023.
 
Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153.
 
 
ACTINIC LICHEN PLANOPILARIS
Lalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160.
 
 
FOLLICULITIS DECALVANS MICROBIOME STUDIES
 
Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30.
 
Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357.
 
 
TNF INHIBITORS IN DISSECTING CELLULITIS
Alzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.

Season Finale (PART 2 of 2): Top 20 Hair Research Studies of 2022

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)
 
 
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
 
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
 
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
 
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
 
 
STUDIES IN SCARRING ALOPECIA
 
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
 
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
 
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
 
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
 
 
STUDIES  IN VARIOUS TOPICS
 
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
 
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
 
 
STUDIES IN PART 1 of PODCAST 
STUDIES IN AGA
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
 
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
 
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
 
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
 
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
 
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
 
STUDY 9: Liang  X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
 
STUDIES IN ALOPECIA AREATA
 
 
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for                  Alopecia Areata. N Engl J Med. 2022 Mar 26.
 
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
 

Season Finale (PART 1 of 2): Top 20 Hair Research Studies of 2022

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in androgenetic alopecia and alopecia areata (studies 1 to 11). Studies 12 to 20 are found in Part 2 (season 3 episode 10)
 
STUDIES IN FEMALE PATTERN HAIR LOSS AND MALE PATTERN HAIR LOSS
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
 
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
 
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
 
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
 
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
 
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
 
STUDY 9: Liang  X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
 
STUDIES IN ALOPECIA AREATA
 
 
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for                  Alopecia Areata. N Engl J Med. 2022 Mar 26.
 
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
 
 
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
 
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
 
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
 
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
 
 
STUDIES IN SCARRING ALOPECIA
 
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
 
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
 
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
 
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
 
 
STUDIES  IN VARIOUS TOPICS
 
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
 
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.

Season 3, Episode 8 (Microneedling for AA, Periodontitis and AA Risk, Microneedling in AGA, Hair Loss in Transgender Patients)

STUDIES REFERENCED
ROLE OF CORTICOSTEROIDS IN THE JAK INHIBITOR ERA
Licata G et al (starts at 7:21). Management of alopecia areata in JAK-inhibitors era: are systemic and topical corticosteroids still useful? Int J Dermatol. 2022 Nov 13.
 
ALOPECIA AREATA AND PERIODONTITIS
Kim JS et al (starts at 17:15). Periodontitis and risk of alopecia areata: A nationwide population-based cohort study in Korea. J Eur Acad Dermatol Venereol. 2022 Nov 17.
 
 
ALOPECIA AREATA AND MICRONEEDLING
Arora A et al (starts at 23:33). Comparative Efficacy of Injection Triamcinolone Acetonide given Intralesionally and through Microneedling in Alopecia areata. Int J Trichology. 2022 Sep-Oct;14(5):156-161.
Chandrashekar BS et al (starts at 27:42). Alopecia areata-successful outcome with microneedling and triamcinolone acetonide. J Cutan Aesthet Surg. 2014 Jan;7(1):63-4.
 
 
HAIR LOSS IN TRANSGENDER INDIVIDUALS
C Cocchetti et al (starts at 32:04). Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI). J Endocrinol Invest. 2022 Nov 8.
 
 
MICRONEEDLING TO TREAT ANDROGENETIC ALOPECIA
 
Lingling Jia et al (starts at 38:21). Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia. J Cosmet Dermatol. 2022 Jul 21.
 
Dhurat R et al (starts at 40:18). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013 Jan;5(1):6-11.
 
Liang  X et al (starts at 43:49).  Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.